1. A predictive model for aggressive non-Hodgkin's lymphoma The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329:987–994. PMID:
8141877.
2. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109:1857–1861. PMID:
17105812.
Article
3. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014; 123:837–842. PMID:
24264230.
Article
4. Lee HG, Choi Y, Kim SY, et al. R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. Blood Res. 2014; 49:107–114. PMID:
25025012.
Article
5. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25:579–586. PMID:
17242396.
6. Le Gouill S, Milpied NJ, Lamy T, et al. First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. J Clin Oncol. 2011; 29(Suppl):abst 8003.
Article
7. Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012; 13:1250–1259. PMID:
23168367.
Article
8. Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013; 369:1681–1690. PMID:
24171516.
Article
9. Vitolo U, Chiappella A, Brusamolino E, et al. Rituximab dose-dense chemotherapy followed by intensified high-dose chemotherapy and autologous stem cell transplantation (HDC+ASCT) significantly reduces the risk of progression compared to standard rituximab dose-dense chemotherapy as first line treatment in young patients with high-risk (aa-IPI 2-3) diffuse large B-cell lymphoma (DLBCL): Final results of phase III randomized trial DLCL04 of the Fondazione Italiana Linfomi (FIL). Blood. 2012; 120(Suppl):abst 688.
Article
10. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28:2373–2380. PMID:
20385988.
11. Inano S, Iwasaki M, Iwamoto Y, et al. Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan. Int J Hematol. 2014; 99:162–168. PMID:
24338743.
Article
12. Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012; 30:4462–4469. PMID:
23091101.
Article
13. Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011; 96:1136–1143. PMID:
21546499.
Article
14. Takasaki H, Hashimoto C, Fujita A, et al. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age. Clin Lymphoma Myeloma Leuk. 2013; 13:404–409. PMID:
23763919.
Article
15. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe dEtude des lymphomes de l'Adulte study. J Clin Oncol. 2000; 18:3025–3030. PMID:
10944137.
Article
16. Yoon JH, Kim JW, Jeon YW, et al. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients. Korean J Intern Med. 2015; 30:362–371. PMID:
25995667.
Article